Oxbow Advisors LLC Buys Shares of 1,796 Novo Nordisk A/S (NYSE:NVO)

Oxbow Advisors LLC bought a new stake in Novo Nordisk A/S (NYSE:NVO) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 1,796 shares of the company’s stock, valued at approximately $231,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Folketrygdfondet grew its position in Novo Nordisk A/S by 1.4% in the first quarter. Folketrygdfondet now owns 8,756,034 shares of the company’s stock valued at $1,124,275,000 after acquiring an additional 124,770 shares during the last quarter. Capital International Investors grew its position in Novo Nordisk A/S by 22.3% in the fourth quarter. Capital International Investors now owns 7,114,931 shares of the company’s stock valued at $736,121,000 after acquiring an additional 1,297,536 shares during the last quarter. Raymond James & Associates grew its position in Novo Nordisk A/S by 12.1% in the first quarter. Raymond James & Associates now owns 3,143,731 shares of the company’s stock valued at $403,655,000 after acquiring an additional 340,549 shares during the last quarter. Natixis Advisors L.P. grew its position in Novo Nordisk A/S by 1.8% in the fourth quarter. Natixis Advisors L.P. now owns 3,052,406 shares of the company’s stock valued at $315,770,000 after acquiring an additional 55,333 shares during the last quarter. Finally, Clearbridge Investments LLC grew its position in Novo Nordisk A/S by 4.0% in the fourth quarter. Clearbridge Investments LLC now owns 2,314,261 shares of the company’s stock valued at $239,410,000 after acquiring an additional 89,152 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on NVO. BMO Capital Markets reissued an “outperform” rating and set a $163.00 price target on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. The Goldman Sachs Group began coverage on Novo Nordisk A/S in a research note on Thursday, May 30th. They set a “buy” rating and a $156.00 price target on the stock. Argus lifted their price target on Novo Nordisk A/S from $125.00 to $160.00 and gave the company a “buy” rating in a research note on Monday, June 10th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research note on Monday, July 1st. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $145.67.

Novo Nordisk A/S Trading Up 2.0 %

Shares of Novo Nordisk A/S stock traded up $2.78 during midday trading on Friday, reaching $142.57. The company had a trading volume of 818,786 shares, compared to its average volume of 4,420,768. The stock has a fifty day moving average price of $137.68 and a 200 day moving average price of $125.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.70 and a quick ratio of 0.50. The firm has a market cap of $639.79 billion, a PE ratio of 48.20, a P/E/G ratio of 1.42 and a beta of 0.41. Novo Nordisk A/S has a fifty-two week low of $77.96 and a fifty-two week high of $148.15.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.06. The company had revenue of $9.52 billion for the quarter, compared to analyst estimates of $9.23 billion. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. On average, equities analysts anticipate that Novo Nordisk A/S will post 3.43 earnings per share for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.